The new site is part of the company's strategic partnership with CSL Limited, which was announced last year. It will become part of Thermo Fisher's global biologics manufacturing network, and approximately 200 employees will join the company.

The Lengnau site, which is expected to be completed in 2022, is a 1.5 million-sq-ft facility that will leverage bioproduction technologies, including both single-use and stainless steel, with up to a 12,500L bioreactor capacity.

Thermo Fisher will initially support manufacturing of CSL's Idelvion for patients with hemophilia B. The company plans to expand the use of the site in the future to include additional biopharma customers.

Thermo Fisher seeks grant proposals that leverage NGS
Thermo Fisher Scientific is accepting new proposals that leverage next-generation sequencing (NGS) for its Oncomine Clinical Research Grant.

Thermo Fisher releases NanoDrop Eight spectrophotometer
Thermo Fisher Scientific is releasing the NanoDrop Eight UV-Vis microvolume spectrophotometer, which replaces the NanoDrop 8000 system, the company announced.

Thermo launches AAV production, digital PCR systems
Thermo Fisher Scientific announced that it has launched two new products. The first product is an adeno-associated virus (AAV) production system, while...

Thermo Fisher announces new spectrometers, facility, more
Thermo Fisher Scientific announced that it is building a manufacturing facility in Tennessee. In addition, it has released a line of spectrometers and...

Thermo Fisher awarded $193M for pipette tip production
Thermo Fisher Scientific will receive $193 million in a contract award from the U.S. Department of Defense to help establish U.S. production of pipette...